Silicone Breast Implant Postmarket Proposals To Be Weighed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's General & Plastic Surgery Devices Panel is likely to place added scrutiny on Mentor's and Inamed's respective proposed silicone breast implant postmarket studies, given the controversy surrounding the devices and heightened public spotlight on the agency's postmarket data lapses
You may also be interested in...
Drug Safety Oversight Initiatives Spur CDRH Postmarket Soul-Searching
The recent spotlight on drug safety is prompting FDA's Center for Devices & Radiological Health to re-examine its regulatory approach to devices
Inamed Silicone Implant Patient Monitoring Plans Allay Rupture Concerns
Inamed's proposal to closely follow patients implanted with silicone gel-filled breast prostheses helped sway FDA's General & Plastic Surgery Devices Panel to recommend conditional approval of the firm's PMA by a 9-6 margin
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.